MENTAX Drug Patent Profile
✉ Email this page to a colleague
When do Mentax patents expire, and when can generic versions of Mentax launch?
Mentax is a drug marketed by Pharmobedient and is included in two NDAs.
The generic ingredient in MENTAX is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mentax
A generic version of MENTAX was approved as butenafine hydrochloride by SUN PHARMA CANADA on November 16th, 2017.
US Patents and Regulatory Information for MENTAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmobedient | MENTAX | butenafine hydrochloride | CREAM;TOPICAL | 020524-001 | Oct 18, 1996 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | MENTAX-TC | butenafine hydrochloride | CREAM;TOPICAL | 021408-001 | Oct 17, 2002 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MENTAX
See the table below for patents covering MENTAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 58126 | ⤷ Start Trial | |
| Canada | 1334973 | DERIVES AMINE, PROCEDES POUR LEUR PREPARATION ET FONGICIDES EN CONTENANT (AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND FUNGICIDES CONTAINING THE SAME) | ⤷ Start Trial |
| China | 1007975 | ⤷ Start Trial | |
| China | 85104330 | ⤷ Start Trial | |
| Germany | 10399014 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MENTAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0164697 | 91031 | Luxembourg | ⤷ Start Trial | 91031, EXPIRES: 20100606 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch